Retatrutide is not "a GLP-1" in the narrow sense
Fig.1 GLP-1 structure diagram GLP-1 drugs on market Current GLP-1 drugs available on market include benaglutide, exenatide, liraglutide, lixisenatide, PLGA-encapsulated long-acting exenatide, albiglutide, dulaglutide, Semaglutide, polyethylene glycol loxenatide injection, and oral semaglutide
LB has served as a consultant for AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk and Sanofi, has participated in speaker bureaus for AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Novo Nordisk and Sanofi, and has received research support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk and Sanofi
But Retatrutides triple-agonist design appears to deliver superior outcomes across multiple metabolic markers
A: Yes, it can be taken on an empty stomach, particularly pre-workout, but some people may prefer taking it with meals to reduce mild stomach discomfort